For the Inventor, By the Inventor

Enter assignee name

Gothenburg, Sweden

Albireo Ab

USPTO Granted Patents = 59

% Expired Patents = 10.2

CIPO Patents = 5

EPO Patents = 26

Trademarks = 11

Forward Citations = 699

Loading Chart...

Loading Chart...

44 inventors (with patents filed for the assignee):

Per-Göran Gillberg (53 out of 54 patents)

Ingemar Starke (33 out of 58 patents)

Santosh Shripad Kulkarni (20 out of 53 patents)

4. Nils Ove Gustafsson (17 out of 20 patents)

5. Jessica Elversson (16 out of 16 patents)

6. Hans Graffner (12 out of 12 patents)

7. Nils-Olof Lindberg (10 out of 11 patents)

8. Jan Mattsson (8 out of 11 patents)

9. Anna-Maria Tivert (7 out of 7 patents)

10. Robert Lundqvist (6 out of 6 patents)

11. Ingvar Ymen (6 out of 10 patents)

12. Eva Byröd (6 out of 6 patents)

13. Rikard Bryland (6 out of 6 patents)

14. Ann-Charlotte Dahlquist (6 out of 6 patents)

15. Martin Hans Bohlin (6 out of 29 patents)

Core Competencies:

IBAT Inhibitors

Liver Diseases

Benzothiazepine Compounds

Odevixibat

Cholestyramine

Inflammatory Bowel Disease

Crystal Modifications

Azetidine Compounds

Functional Gastrointestinal Disorders

Progressive Familial Intrahepatic Cholestasis

Bile Acid Modulators

Pharmaceutical Formulation

59 patents: Sort by Forward Citations

1. 12545705 - IBAT inhibitors for the treatment of liver diseases (2026-02-10),

2. 12508234 - PHARMACEUTICAL FORMULATION OF ODEVIXIBAT (2025-12-30),

3. 12447156 - Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors (2025-10-21),

4. 12365658 - Benzothia(di)azepine compounds and their use as bile acid modulators (2025-07-22),

5. 12202809 - Benzothia(di)azepine compounds and their use as bile acid modulators (2025-01-21),

6. 12187812 - IBAT inhibitors for the treatment of liver diseases (2025-01-07),

7. 12187690 - Benzothiadiazepine compounds and their use as bile acid modulators (2025-01-07),

8. 12134606 - Benzothia(di)azepine compounds and their use as bile acid modulators (2024-11-05),

9. 12091394 - Crystal modifications of odevixibat (2024-09-17),

10. 12060338 - Benzothia(di)azepine compounds and their use as bile acid modulators (2024-08-13),

11. 12024495 - Benzothiazepine compounds and their use as bile acid modulators (2024-07-02),

12. 11891368 - Benzothia(di)azepine compounds and their use as bile acid modulators (2024-02-06),

13. 11802115 - Pharmaceutical formulation of odevixibat (2023-10-31),

14. 11801226 - Pharmaceutical formulation of odevixibat (2023-10-31),

15. 11773071 - Benzothiazepine compounds and their use as bile acid modulators (2023-10-03),

Albireo Ab, based in Gothenburg, Sweden, specializes in innovative treatments for liver diseases, focusing on the development of IBAT inhibitors. The company is dedicated to addressing unmet medical needs in conditions such as cholestatic liver diseases and inflammatory bowel disease. Its core technologies include the proprietary compound Odevixibat and various benzothiazepine and azetidine compounds, which aim to improve patient outcomes through targeted therapeutic approaches. Albireo's research efforts are centered on advancing liver disease treatment options globally.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

59 Patents

#20 in Gothenburg

#119 in Sweden

#12,219 in the World

Gothenburg, Sweden

Albireo Ab

Forward Citations = 699

44 inventors:

Per-Göran Gillberg (53 out of 54 patents)

Ingemar Starke (33 out of 58 patents)

Santosh Shripad Kulkarni (20 out of 53 patents)

4. Nils Ove Gustafsson (17 out of 20 patents)

5. Jessica Elversson (16 out of 16 patents)

Please report any incorrect information to [email protected]

Loading…